Viatris Closes $36.50/Share Pacira Buy as Tender Hits 66.46%
VTRS sits 99% above its 52-week low of $10.15.
Summary
Viatris completed its $36.50-per-share all-cash acquisition of Pacira after the tender offer drew 66.46% of shares, clearing the minimum condition; Pacira is now a wholly owned subsidiary and will be delisted from Nasdaq.
Key Events · M&A and Partnerships · VTRS
-
Tender Offer Closes at 66.46%
By the November 16, 2026 expiration, 32,929,780 Pacira shares had been validly tendered and not withdrawn, representing approximately 66.46% of shares outstanding and satisfying the minimum condition.
-
Merger Completed Without Pacira Vote
On November 17, 2026, Viatris accepted all tendered shares for payment at $36.50 per share in cash and merged its Peach Purchaser Sub into Pacira under DGCL Section 251(h), making Pacira a wholly owned subsidiary.
-
Delisting and Deregistration Ahead
As promptly as practicable after the effective time, Pacira shares will be delisted from the Nasdaq Global Select Market and deregistered under the Exchange Act.
-
Acquired Revenue Guidance $90M-$100M
For the period from November 17, 2026 through December 31, 2026, Viatris expects the Pacira acquisition to contribute total revenues of between $90 million and $100 million.
Analysis · VTRS · Life Sciences
With 32,929,780 shares tendered — about 66.46% of Pacira's outstanding stock — the minimum condition was cleared when the offer expired on November 16, so Viatris accepted payment on November 17 and immediately completed the merger under Delaware's short-form Section 251(h) provision without a Pacira shareholder vote. Pacira is now a wholly owned Viatris subsidiary, and its shares will be delisted from Nasdaq and deregistered. The deal adds Pacira's non-opioid pain portfolio (EXPAREL, ZILRETTA) and is expected to contribute $90 million to $100 million of revenue in the roughly six weeks remaining in 2026. For Viatris holders the remaining questions are integration and whether the acquired revenue and cost synergies offset the $1.65 billion cash outlay; the outstanding stockholder litigation over Pacira's 14D-9 disclosure did not block closing.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VTRS was trading at $20.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.8B. The 52-week trading range was $10.15 to $21.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.